SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following the finalization of its $250 million acquisition of Ask Sage, a key generative AI platform for secure defense and government applications. This strategic move is driving significant bullish sentiment among investors who anticipate new government and TSA contracts, reinforcing its position in the AI defense sector. However, ongoing discussions and repeatedly postponed votes concerning increased authorized shares are causing investor debate, contributing to the stock's notable volatility.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending due to its exceptionally low public float, positioning it as a prime candidate for a short squeeze. The community is actively discussing the company's significant cash reserves relative to its market valuation, fueling speculation about potential strategic alternatives like a merger. Many believe this combination of factors points to substantial untapped value and potential for rapid upward movement, drawing comparisons to other recent parabolic movers.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is actively trending as investors anticipate a potential housing market rebound in early 2026, driven by lower interest rates and the "January effect" for small-cap tech. Community sentiment is divided, with bulls optimistic about the company's strategic shift towards AI-powered real estate and its battle-tested leadership, while skeptics question past performance and the long-term profitability of its business model.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following its announcement of record December and Q4 2025 vehicle deliveries, surpassing key competitors. The community is buzzing with speculation about whether these strong delivery figures will finally translate into profitability in Q4 or 2026, and if the stock price will reflect the improving fundamentals amid ongoing frustration over perceived market manipulation. Many highlight the expanding battery swap network and multi-brand strategy as crucial long-term growth drivers.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to extreme recent volatility, including a significant price drop from earlier highs, which is happening alongside news of its blockchain technology expanding into luxury and fashion traceability. Community sentiment is sharply divided, with proponents highlighting its disruptive tech and potential for a short squeeze amidst a low float and high cost to borrow, while skeptics point to a history of reverse splits and ongoing dilution concerns.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending due to intense community debate surrounding an upcoming shareholder meeting, where a significant increase in authorized shares is a key proposal, fueling investor concerns over potential dilution and perceived management self-interest given the stock's underperformance against Ethereum. While some investors view recent declines as a buying opportunity, anticipating future staking revenue and a broader market rebound, many others express strong bearish sentiment, criticizing leadership actions and questioning the company's financial strategy.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending after announcing a strategic manufacturing partnership and a private placement that is expected to strengthen its balance sheet and scale production. This has ignited intense community discussion, with many anticipating a short squeeze fueled by its low public float, while others express caution regarding potential dilution from the private placement.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending as the community highlights its recent contract wins, including a significant European commercial space deal, and its diversified role across space infrastructure and defense systems. Many investors are actively discussing short squeeze potential and perceive the company as significantly undervalued, anticipating substantial long-term growth within the burgeoning space sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors eagerly await its Q4 delivery numbers, a key data point expected to drive significant price action. Bulls are anticipating strong growth from the energy division and future robotaxi deployments, while bears point to slowing EV sales, unfulfilled autonomy promises, and an elevated valuation, fueling a heated debate over the stock's direction.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with intense community focus on an anticipated "Clarity Act" and potential supply shock, alongside recent developments like XRP ETF inflows and expanded institutional partnerships. While many foresee substantial price surges driven by these catalysts, there's also ongoing debate and frustration regarding its past price stagnation and the implications of Ripple's scheduled escrow releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 186.2% in the 3rd quarter, according to the company in its most recent...

Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports...

Aptars Bidose Nasal System Delivers CARDAMYST (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the...

What is HC Wainwright's Estimate for MIST FY2026 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report...

Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 4,480 call options on the company. This is an...

<ul class="summary-bullets"><li>Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia and restore sinus rhythm.</li><li>The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.</li><li>Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter of 2026.</li></ul>Shares of Milestone Pharmaceuticals Inc. (MIST) rose nearly 32% in Monday’s pre-market after the company received approval from the U.S. Food and Drug Administration (FDA) for its first commercial product late Friday.Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia (PSVT) and restore sinus rhythm.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MIST">Milestone stock</a> trended in the ‘extremely bullish’ territory, while message volumes were at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Cardamyst Approval</h2>Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT. The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter (Q1) of 2026.“Cardamyst is a novel at-the-ready treatment option that addresses the unpredictable impact of PSVT by offering patients the freedom to manage episodes anytime and anywhere,” said Joseph Oliveto, CEO, Milestone Pharmaceuticals.<h2 class="st-heading-2">Clinical Data</h2>Milestone stated that Cardamyst’s approval by the FDA is based on safety data from more than 1,800 participants and over 2,000 episodes of PSVT.The company said that participants using Cardamyst were twice as likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster than with a placebo.<h2 class="st-heading-2">Retail Optimistic</h2>Retail users on Stocktwits expressed their optimism around the company and Cardamyst following the FDA approval.One user said that the most challenging part for the company was over after the approval, adding that those who are long on the stock have “ZERO to worry about here.”<stembedurl>https://stocktwits.com/Wut_About_Bob/message/639158529</stembedurl>Another user dismissed concerns that this is a “sell the news” event, adding that they are “waiting with 0 worries.”<stembedurl>https://stocktwits.com/MarketILF/message/639154331</stembedurl><a href="https://stocktwits.com/symbol/MIST">MIST stock</a> is up 2% year-to-date and 30% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-fully-priced-for-autonomy-ev-demand-weakens-gary-black/cLeECtqRE8s">Is TSLA Stock Fully Priced For Autonomy? Here's What Gary Black Thinks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Equity

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

FDA Approves Milestone Pharma' CARDAMYST, First Self-Administered Treatment For PSVT

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription...

Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of unusually large options trading on Monday. Traders bought 3,255 call options on the stock. This represents an increase...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIST News

MISTMilestone Pharmaceuticals Inc